MHRA approves catumaxomab for cancer-related fluid build-up in the abdomen
October 7, 2026
AI summary — for doctors, generated from the source snippet
Why it matters
The UK regulator licensed catumaxomab for malignant ascites and will keep its safety under close review.
Clinical relevance
Gives oncologists an option for malignant ascites in the UK market.
Who should care
This is an AI-generated summary of the source's own press release/snippet, not a clinical recommendation. Verify against the original source before acting on it.
Original source summary
As with all licensed medicines, the MHRA will keep the safety and effectiveness of catumaxomab under close review.
Verbatim from MHRA (UK)'s own feed — "MHRA approves catumaxomab to treat cancer-related fluid build-up in the abdomen"
Want more like this?
Browse more from the feed. A free account unlocks the full feed, saving and communities.
More medical news